Infant DevelopmentDIMPLENCT06107933
Developmental Impacts of Microplastics Exposure in Early Life
An observational study of Infant Development and Breast Feeding, run by Johns Hopkins Bloomberg School of Public Health at 1 site in United States.
Trial summary
The goal of this observational study is to characterize and evaluate micro- and nano-plastic (MNP) exposures among mothers and infants in mother-infant dyads 1 or 3 months postpartum living in Baltimore, Maryland. Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Infant Development, Breast Feeding, Environmental Exposure
- What is being tested?
- Observational only
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Oct 2023to 1 Jan 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study will include 20 mother-infant pairs from Baltimore City and County. We will be studying lactating mothers at 1 or 3 months postpartum ±2 weeks.
Who may be able to join
- All gender expressions
- Mothers at 1 or 3 months postpartum (± 2 weeks)
- Intent to exclusively breastfeed for ≥ 6 months
- Nulliparous and singleton births
- Receiving only breast milk from the mother, with no formula supplementation
Who cannot join
- Physical, mental, or cognitive disability that prevents participation; current incarceration
- Chronic conditions in mother and/or infant (e.g., heart disease, cancer, autoimmune disease, diabetes, intestinal bowel syndrome/disease), conditions diagnosed for the first time during pregnancy (e.g. gestational diabetes), neurological conditions in mother and/or infant (e.g. epilepsy, seizures), psychological conditions in mother and/or infant (e.g. bipolar disorder), or neurological/psychological conditions diagnosed in mother during or immediately after pregnancy (e.g. postpartum depression)
- Previously diagnosed with any major illness (e.g., intrauterine growth restriction, birth asphyxia, cancer) or eating disorder or previous gastric band surgery
- Maternal antibiotic use during pregnancy or the postpartum period. Infant antibiotic use at any time during life or taking medications that could affect plastic exposure or the microbiome, such as medications administered via a plastic syringe.
- Use of any breast pump except the Silicon Breast Pump for the 14 days prior to the clinical visit.
- PHQ9 score greater than or equal to 10 indicating clinically relevant symptoms of moderate or worse depression
- Infants who are intersex
- Smoking, drug use (including marijuana use), or alcohol abuse
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
East Baltimore Pediatric Inpatient and Outpatient Clinical Research Unit
Baltimore, Maryland, 21287
Rachel Salamone, RN, 410-614-6365, rsalamo3@jhu.edu
About this study
Official title: Developmental Impacts of MicroPLastics Exposure in Early Life
The goal of this observational study is to characterize and evaluate micro- and nano-plastic (MNP) exposures among mothers and infants in mother-infant dyads 1 or 3 months postpartum living in Baltimore, Maryland. The main questions it aims to answer are:
- What MNPs are present in breastmilk and maternal blood samples and in their infants stool sample?
- Are there associations between amount of maternal MNPs in breast milk and mass of MNP particles in infant stool?
- Which environmental and lifestyle factors are most predictive of maternal MNP burden?
- Is infant exposure to MNPs associated with birth weight and postnatal growth trajectories?
Read more
Participants will:
- Complete several questionnaires assessing medical histories, lifestyle factors, environmental exposures, eating behaviors, etc.
- Provide biological specimens including: maternal blood, stool, and breastmilk; infant stool
- Clinical visit to have anthropometric measures documented including maternal height and weight, infant weight, length, and skin-fold thickness
Read the detailed description
The proposed pilot study will establish a new cohort of healthy, lactating women from Baltimore City and Baltimore County, Maryland. By recruiting women from these two regions, the investigators will be able to ensure that the pilot study covers a diverse geographical range with varying levels of air pollution exposure and social determinants of health (SDoH). Study participants will be 1 or 3 months postpartum (+/- 2 weeks) and report exclusive breastfeeding. The investigators will also biobank maternal stool samples for future funding applications that will additionally examine the gut microbiome and fecal metabolome.
Height, Weight, Blood Pressure, and other Anthropometric Measures: Maternal height and weight will be measured using a calibrated medical scale and a commercial stadiometer. Infant weight will be measured in duplicate on a digital scale accurate to the nearest 10 g and length will be measured in duplicate to the nearest 0.1 cm using an Infantometer and the standardized World Health Organization (WHO) approach. Infant skinfold thickness will be measured at four sites with Holtain skinfold callipers. Maternal weight will be recorded to the nearest 0.1 kg and height will be recorded to the nearest 0.1 cm. Automated blood pressure using appropriate cuffs will be used to obtain three readings of blood pressure, from which the average value will be recorded, per recommendations of the American Heart Association.
Assessment of Food Intake; Physical Activity: Dietary data will be collected using the National Cancer Institute (NCI) National Health and Nutritional Examination Survey (NHANES) Food Frequency Questionnaire. The questionnaire is designed to capture information about food intake over the prior month, and includes questions outlining consumption of fruits, vegetables, dairy products, whole grain and fiber, sugar, and red and processed meats. The questionnaire will be administered on the web with a research assistant nearby to assist with any questions. Given the investigators are interested in microplastics exposure from food, additional dietary data will be collected through the administration of Nutrition Data System for Research (NDSR) 24-hour dietary recalls which will be administered over the phone by a registered dietician or study staff under the direct supervision of a registered dietician. The investigators will ask mothers to complete 3 dietary recalls for themselves and 3 for their infant, for ideally 2 weekdays and a weekend. One dietary recall for both mother and infant will be completed during the Clinical Visit at the Clinical Research Unit (CRU). Research assistants will work together with participants to establish which days are best suited for them to complete subsequent recalls. Finally, to assess the quantity of milk consumed by infants during a single feeding, the investigators will weigh the infants at the study visit before feeding. Then mothers will be asked to breastfeed their infant. Upon completion of feeding, the investigators will re-weigh the infants to roughly capture the amount of milk consumed.
Maternal and Infant Fecal Samples: Fecal collection kits will be given to eligible participants. To avoid plastic contamination, maternal fecal collection kits will include an absorbent pad covering any plastic on the stool collection hat, gloves, a metal spoon, and glass container. For the infant stool collection, mothers will be provided with a diaper, bee's wrap; cloth, and all collection supplies that are free of plastic. The investigators will deliver these collection supplies and instructions to participants prior to their visit so that participants may collect these samples at home. The investigators will ask them to take the samples within 24 hours of the visit time to preserve the microbial composition of the stool samples. The instructions will specify that samples should be stored in the refrigerator until their visit. The investigators will provide a cooler for participants to transport the samples to the CRU. If for any reason, participants were not able to obtain these samples at home, participants will be allowed to collect them during the visit, If collected at the clinical visit, maternal and infant stool samples will be transferred into 3-4 glass vials and stored in a -4°C fridge for 24 hours prior to being stored at -80°C for MNP and gut microbiome sequencing. Fecal collection tubes utilize a fecal preservative, which prevents changes to aerobic and anaerobic bacteria that can occur during shipment. Fecal sequencing will be performed at Emory University (Dr. Doug Walker). Only de-identified samples will be sent to Dr. Walker's lab. DNA will be sequenced on the Illumina HiSeq 4000 platform. Microbial composition profiles will be predicted using MetaPhlan. Samples will be functionally mapped using HUMAnN2 to obtain abundance level of gene families from the UniProt Reference Clusters that will be further mapped to MetaCyc metabolic pathways database. Genes will be grouped in clusters of orthologous groups from EggNOG data. Gene family abundances will be grouped into broader functional categories based on annotation for the UniProt gene ontology. For the metabolomics analysis, fecal samples will be analyzed using ultra-performance liquid chromatography (UPLC) and high resolution/tandem mass spectrometry (MS/MS) by Metabolon. Compounds of exogenous, human, and microbial origin will be identified by comparison to library entries of purified standards or recurrent unknown entities. Metabolon maintains a reference library of more than 4,500 known metabolites and more than 9,000 novel metabolites. Biochemical identifications will be based on three criteria: retention index, accurate mass match to the library +/- 10 ppm, and the MS/MS forward and reverse scores between the experimental data and authentic standards.
Breast Milk Expression: Due to potential exposures from feeding breast milk from plastic bottles, all mothers will be asked to only feed their infants from the breast for 14 days prior to infant stool collection. Similar to the stool collection supplies, the investigators will provide mothers with a Haakaa Silicone Breast Pump, silicone storage container with cap, and instructions prior to the study visit. Mothers will be asked to provide a full expression of a single breast. If mothers are uncomfortable providing a full expression, study coordinators will work with mothers to determine an amount appropriate for collection. The investigators will collect a minimum of roughly 4g of breast milk. If mothers are unable to collect their breastmilk sample before the visit, mothers will be provided with a quiet, private CRU study room to pump using a Haakaa Silicone Breast Pump into a silicone storage container. Following collection, a member of our study team will aliquot measures into glass sterile tubes for storage. Following collection, all samples will be stored at -80 degrees C prior to processing and analysis.
Blood Draw: Blood draws will be collected (40mL) for microplastics analysis. Blood will be collected using a stainless steel 21G needle that is connected to a glass container under vacuum, so blood drawn directly from participant is deposited in the glass vacutainer. Glass vacutainers will have a rubber seal for storage.
- Conditions
- Infant Development, Breast Feeding, Environmental Exposure
- Being tested
- Observational only
- Keywords
- microplastic, breastmilk, infant microplastic exposure, gut microbiome, fecal metabolome
- Medical subject headings
- Breast Feeding
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Observational onlyOther
Exposure to micro and nano plastics
| Study group | Role | What they receive |
|---|---|---|
| City Mother-Infant Pairs | Mother-infant pairs living in a Baltimore City, Maryland zip code exposed to micro and nano plastics. Receives: Other: Observational only | |
| County Mother-Infant Pairs | Mother-infant pairs living in a Baltimore County, Maryland zip code exposed to micro and nano plastics. Receives: Other: Observational only |
What is being measured
The primary outcome is the main question the study is designed to answer.
Microplastic composition in maternal breastmilk
MNPs are measured using pyrolysis GC-HRMS using a Frontier Multi-Shot Pyrolyzer with Auto-Shot Sampler interfaced to a Trace 1310 gas chromatography system and Thermo Scientific Q Exactive GC Orbitrap GC-MS/MS.
Measured: 1 or 3 months +/- 2 weeks postpartum
Microplastic composition in maternal venous blood
MNPs are measured using pyrolysis GC-HRMS using a Frontier Multi-Shot Pyrolyzer with Auto-Shot Sampler interfaced to a Trace 1310 gas chromatography system and Thermo Scientific Q Exactive GC Orbitrap GC-MS/MS.
Measured: 1 or 3 months +/- 2 weeks postpartum
Microplastic composition in infant stool
MNPs are measured using pyrolysis GC-HRMS using a Frontier Multi-Shot Pyrolyzer with Auto-Shot Sampler interfaced to a Trace 1310 gas chromatography system and Thermo Scientific Q Exactive GC Orbitrap GC-MS/MS.
Measured: 1 or 3 months +/- 2 weeks postpartum
Infant weight
Infant weight will be measured in duplicate on a digital scale accurate to the nearest 10 g
Measured: 1 or 3 months +/- 2 weeks postpartum
Infant length
Infant length will be measured in duplicate to the nearest 0.1 cm using an Infantometer.
Measured: 1 or 3 months +/- 2 weeks postpartum
Infant skinfold thickness
Infant skinfold thickness will be measured at four sites with Holtain skinfold callipers
Measured: 1 or 3 months +/- 2 weeks postpartum
Secondary outcomes (1)
Maternal stool microbiome composition
Maternal stool will be stored in cryovials at -80C for future metagenomic sequencing to analyze the composition of the gut microbiome.
Measured: 1 or 3 months +/- 2 weeks postpartum
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Oct 2023
- Study start1 Oct 2023
- Primary completion31 Dec 2026 (estimated)
- Study completion1 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (106)Papers the sponsor has linked to this study.
- Other trials for Infant DevelopmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Sponsor type
- University, hospital or other
- Collaborators
- Emory University, Sonoma Technology, Inc.
- Responsible party
- Sponsor
- Investigators
- Tanya L Alderete, PhD, Principal investigator, Johns Hopkins Bloomberg School of Public Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06107933
- Sponsor's protocol ID
- IRB00030652
- Other IDs
- 23-0314
- Acronym
- DIMPLE
- Status last verified
- Jun 2026
- First submitted
- 3 Oct 2023
- Last updated
- 9 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Geyer R, Jambeck JR, Law KL. Production, use, and fate of all plastics ever made. Sci Adv. 2017 Jul 19;3(7):e1700782. doi: 10.1126/sciadv.1700782. eCollection 2017 Jul.
PubMed 28776036Veidis EM, LaBeaud AD, Phillips AA, Barry M. Tackling the Ubiquity of Plastic Waste for Human and Planetary Health. Am J Trop Med Hyg. 2021 Nov 8;106(1):12-14. doi: 10.4269/ajtmh.21-0968. No abstract available.
PubMed 34749307Usman S, Abdull Razis AF, Shaari K, Azmai MNA, Saad MZ, Mat Isa N, Nazarudin MF. The Burden of Microplastics Pollution and Contending Policies and Regulations. Int J Environ Res Public Health. 2022 Jun 1;19(11):6773. doi: 10.3390/ijerph19116773.
PubMed 35682361Law KL, Starr N, Siegler TR, Jambeck JR, Mallos NJ, Leonard GH. The United States' contribution of plastic waste to land and ocean. Sci Adv. 2020 Oct 30;6(44):eabd0288. doi: 10.1126/sciadv.abd0288. Print 2020 Oct.
PubMed 33127684Kannan K, Vimalkumar K. A Review of Human Exposure to Microplastics and Insights Into Microplastics as Obesogens. Front Endocrinol (Lausanne). 2021 Aug 18;12:724989. doi: 10.3389/fendo.2021.724989. eCollection 2021.
PubMed 34484127Sendra M, Pereiro P, Figueras A, Novoa B. An integrative toxicogenomic analysis of plastic additives. J Hazard Mater. 2021 May 5;409:124975. doi: 10.1016/j.jhazmat.2020.124975. Epub 2020 Dec 26.
PubMed 33388451Rustagi N, Pradhan SK, Singh R. Public health impact of plastics: An overview. Indian J Occup Environ Med. 2011 Sep;15(3):100-3. doi: 10.4103/0019-5278.93198.
PubMed 22412286Yang H, He Y, Yan Y, Junaid M, Wang J. Characteristics, Toxic Effects, and Analytical Methods of Microplastics in the Atmosphere. Nanomaterials (Basel). 2021 Oct 17;11(10):2747. doi: 10.3390/nano11102747.
PubMed 34685192Yong CQY, Valiyaveettil S, Tang BL. Toxicity of Microplastics and Nanoplastics in Mammalian Systems. Int J Environ Res Public Health. 2020 Feb 26;17(5):1509. doi: 10.3390/ijerph17051509.
PubMed 32111046Leslie HA, van Velzen MJM, Brandsma SH, Vethaak AD, Garcia-Vallejo JJ, Lamoree MH. Discovery and quantification of plastic particle pollution in human blood. Environ Int. 2022 May;163:107199. doi: 10.1016/j.envint.2022.107199. Epub 2022 Mar 24.
PubMed 35367073Luqman A, Nugrahapraja H, Wahyuono RA, et al. Microplastic Contamination in Human Stools, Foods, and Drinking Water Associated with Indonesian Coastal Population. Environments. 2021;8(12):138. doi:10.3390/environments8120138
Zhang N, Li YB, He HR, Zhang JF, Ma GS. You are what you eat: Microplastics in the feces of young men living in Beijing. Sci Total Environ. 2021 May 1;767:144345. doi: 10.1016/j.scitotenv.2020.144345. Epub 2020 Dec 31.
PubMed 33434834Schwabl P, Koppel S, Konigshofer P, Bucsics T, Trauner M, Reiberger T, Liebmann B. Detection of Various Microplastics in Human Stool: A Prospective Case Series. Ann Intern Med. 2019 Oct 1;171(7):453-457. doi: 10.7326/M19-0618. Epub 2019 Sep 3.
PubMed 31476765Yan Z, Liu Y, Zhang T, Zhang F, Ren H, Zhang Y. Analysis of Microplastics in Human Feces Reveals a Correlation between Fecal Microplastics and Inflammatory Bowel Disease Status. Environ Sci Technol. 2022 Jan 4;56(1):414-421. doi: 10.1021/acs.est.1c03924. Epub 2021 Dec 22.
PubMed 34935363Liu S, Guo J, Liu X, Yang R, Wang H, Sun Y, Chen B, Dong R. Detection of various microplastics in placentas, meconium, infant feces, breastmilk and infant formula: A pilot prospective study. Sci Total Environ. 2023 Jan 1;854:158699. doi: 10.1016/j.scitotenv.2022.158699. Epub 2022 Sep 13.
PubMed 36108868
Study at a glance
From the registry record, last updated by the sponsor on 9 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Developmental Impacts of MicroPLastics Exposure in Early Life
- ClinicalTrials.gov ID
- NCT06107933
- Acronym / sponsor ID
- DIMPLE / IRB00030652
- Conditions
- Infant Development, Breast Feeding, Environmental Exposure
- Keywords
- microplastic, breastmilk, infant microplastic exposure, gut microbiome, fecal metabolome
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Johns Hopkins Bloomberg School of Public HealthUniversity, hospital or other
- Collaborators
- Emory University, Sonoma Technology, Inc.
- Study start
- 1 Oct 2023 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 1 Jan 2027 (estimated)
- First posted
- 30 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to characterize and evaluate micro- and nano-plastic (MNP) exposures among mothers and infants in mother-infant dyads 1 or 3 months postpartum living in Baltimore, Maryland. The main questions it aims to answer are:
- What MNPs are present in breastmilk and maternal blood samples and in their infants stool sample?
- Are there associations between amount of maternal MNPs in breast milk and mass of MNP particles in infant stool?
- Which environmental and lifestyle factors are most predictive of maternal MNP burden?
- Is infant exposure to MNPs associated with birth weight and postnatal growth trajectories?
Participants will:
- Complete several questionnaires assessing medical histories, lifestyle factors, environmental exposures, eating behaviors, etc.
- Provide biological specimens including: maternal blood, stool, and breastmilk; infant stool
- Clinical visit to have anthropometric measures documented including maternal height and weight, infant weight, length, and skin-fold thickness
Detailed description
The proposed pilot study will establish a new cohort of healthy, lactating women from Baltimore City and Baltimore County, Maryland. By recruiting women from these two regions, the investigators will be able to ensure that the pilot study covers a diverse geographical range with varying levels of air pollution exposure and social determinants of health (SDoH). Study participants will be 1 or 3 months postpartum (+/- 2 weeks) and report exclusive breastfeeding. The investigators will also biobank maternal stool samples for future funding applications that will additionally examine the gut microbiome and fecal metabolome.
Height, Weight, Blood Pressure, and other Anthropometric Measures: Maternal height and weight will be measured using a calibrated medical scale and a commercial stadiometer. Infant weight will be measured in duplicate on a digital scale accurate to the nearest 10 g and length will be measured in duplicate to the nearest 0.1 cm using an Infantometer and the standardized World Health Organization (WHO) approach. Infant skinfold thickness will be measured at four sites with Holtain skinfold callipers. Maternal weight will be recorded to the nearest 0.1 kg and height will be recorded to the nearest 0.1 cm. Automated blood pressure using appropriate cuffs will be used to obtain three readings of blood pressure, from which the average value will be recorded, per recommendations of the American Heart Association.
Assessment of Food Intake; Physical Activity: Dietary data will be collected using the National Cancer Institute (NCI) National Health and Nutritional Examination Survey (NHANES) Food Frequency Questionnaire. The questionnaire is designed to capture information about food intake over the prior month, and includes questions outlining consumption of fruits, vegetables, dairy products, whole grain and fiber, sugar, and red and processed meats. The questionnaire will be administered on the web with a research assistant nearby to assist with any questions. Given the investigators are interested in microplastics exposure from food, additional dietary data will be collected through the administration of Nutrition Data System for Research (NDSR) 24-hour dietary recalls which will be administered over the phone by a registered dietician or study staff under the direct supervision of a registered dietician. The investigators will ask mothers to complete 3 dietary recalls for themselves and 3 for their infant, for ideally 2 weekdays and a weekend. One dietary recall for both mother and infant will be completed during the Clinical Visit at the Clinical Research Unit (CRU). Research assistants will work together with participants to establish which days are best suited for them to complete subsequent recalls. Finally, to assess the quantity of milk consumed by infants during a single feeding, the investigators will weigh the infants at the study visit before feeding. Then mothers will be asked to breastfeed their infant. Upon completion of feeding, the investigators will re-weigh the infants to roughly capture the amount of milk consumed.
Maternal and Infant Fecal Samples: Fecal collection kits will be given to eligible participants. To avoid plastic contamination, maternal fecal collection kits will include an absorbent pad covering any plastic on the stool collection hat, gloves, a metal spoon, and glass container. For the infant stool collection, mothers will be provided with a diaper, bee's wrap; cloth, and all collection supplies that are free of plastic. The investigators will deliver these collection supplies and instructions to participants prior to their visit so that participants may collect these samples at home. The investigators will ask them to take the samples within 24 hours of the visit time to preserve the microbial composition of the stool samples. The instructions will specify that samples should be stored in the refrigerator until their visit. The investigators will provide a cooler for participants to transport the samples to the CRU. If for any reason, participants were not able to obtain these samples at home, participants will be allowed to collect them during the visit, If collected at the clinical visit, maternal and infant stool samples will be transferred into 3-4 glass vials and stored in a -4°C fridge for 24 hours prior to being stored at -80°C for MNP and gut microbiome sequencing. Fecal collection tubes utilize a fecal preservative, which prevents changes to aerobic and anaerobic bacteria that can occur during shipment. Fecal sequencing will be performed at Emory University (Dr. Doug Walker). Only de-identified samples will be sent to Dr. Walker's lab. DNA will be sequenced on the Illumina HiSeq 4000 platform. Microbial composition profiles will be predicted using MetaPhlan. Samples will be functionally mapped using HUMAnN2 to obtain abundance level of gene families from the UniProt Reference Clusters that will be further mapped to MetaCyc metabolic pathways database. Genes will be grouped in clusters of orthologous groups from EggNOG data. Gene family abundances will be grouped into broader functional categories based on annotation for the UniProt gene ontology. For the metabolomics analysis, fecal samples will be analyzed using ultra-performance liquid chromatography (UPLC) and high resolution/tandem mass spectrometry (MS/MS) by Metabolon. Compounds of exogenous, human, and microbial origin will be identified by comparison to library entries of purified standards or recurrent unknown entities. Metabolon maintains a reference library of more than 4,500 known metabolites and more than 9,000 novel metabolites. Biochemical identifications will be based on three criteria: retention index, accurate mass match to the library +/- 10 ppm, and the MS/MS forward and reverse scores between the experimental data and authentic standards.
Breast Milk Expression: Due to potential exposures from feeding breast milk from plastic bottles, all mothers will be asked to only feed their infants from the breast for 14 days prior to infant stool collection. Similar to the stool collection supplies, the investigators will provide mothers with a Haakaa Silicone Breast Pump, silicone storage container with cap, and instructions prior to the study visit. Mothers will be asked to provide a full expression of a single breast. If mothers are uncomfortable providing a full expression, study coordinators will work with mothers to determine an amount appropriate for collection. The investigators will collect a minimum of roughly 4g of breast milk. If mothers are unable to collect their breastmilk sample before the visit, mothers will be provided with a quiet, private CRU study room to pump using a Haakaa Silicone Breast Pump into a silicone storage container. Following collection, a member of our study team will aliquot measures into glass sterile tubes for storage. Following collection, all samples will be stored at -80 degrees C prior to processing and analysis.
Blood Draw: Blood draws will be collected (40mL) for microplastics analysis. Blood will be collected using a stainless steel 21G needle that is connected to a glass container under vacuum, so blood drawn directly from participant is deposited in the glass vacutainer. Glass vacutainers will have a rubber seal for storage.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| City Mother-Infant Pairs | – | Other: Observational onlyMother-infant pairs living in a Baltimore City, Maryland zip code exposed to micro and nano plastics. |
| County Mother-Infant Pairs | – | Other: Observational onlyMother-infant pairs living in a Baltimore County, Maryland zip code exposed to micro and nano plastics. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study will include 20 mother-infant pairs from Baltimore City and County. We will be studying lactating mothers at 1 or 3 months postpartum ±2 weeks.
Key inclusion criteria (5 listed)
- All gender expressions
- Mothers at 1 or 3 months postpartum (± 2 weeks)
- Intent to exclusively breastfeed for ≥ 6 months
- Nulliparous and singleton births
- Receiving only breast milk from the mother, with no formula supplementation
Key exclusion criteria (8 listed)
- Physical, mental, or cognitive disability that prevents participation; current incarceration
- Chronic conditions in mother and/or infant (e.g., heart disease, cancer, autoimmune disease, diabetes, intestinal bowel syndrome/disease), conditions diagnosed for the first time during pregnancy (e.g. gestational diabetes), neurological conditions in mother and/or infant (e.g. epilepsy, seizures), psychological conditions in mother and/or infant (e.g. bipolar disorder), or neurological/psychological conditions diagnosed in mother during or immediately after pregnancy (e.g. postpartum depression)
- Previously diagnosed with any major illness (e.g., intrauterine growth restriction, birth asphyxia, cancer) or eating disorder or previous gastric band surgery
- Maternal antibiotic use during pregnancy or the postpartum period. Infant antibiotic use at any time during life or taking medications that could affect plastic exposure or the microbiome, such as medications administered via a plastic syringe.
- Use of any breast pump except the Silicon Breast Pump for the 14 days prior to the clinical visit.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Observational onlyExposure to micro and nano plastics | Other | City Mother-Infant Pairs, County Mother-Infant Pairs |
Primary outcome
Microplastic composition in maternal breastmilk
Time frame: 1 or 3 months +/- 2 weeks postpartum
MNPs are measured using pyrolysis GC-HRMS using a Frontier Multi-Shot Pyrolyzer with Auto-Shot Sampler interfaced to a Trace 1310 gas chromatography system and Thermo Scientific Q Exactive GC Orbitrap GC-MS/MS.
Microplastic composition in maternal venous blood
Time frame: 1 or 3 months +/- 2 weeks postpartum
MNPs are measured using pyrolysis GC-HRMS using a Frontier Multi-Shot Pyrolyzer with Auto-Shot Sampler interfaced to a Trace 1310 gas chromatography system and Thermo Scientific Q Exactive GC Orbitrap GC-MS/MS.
Microplastic composition in infant stool
Time frame: 1 or 3 months +/- 2 weeks postpartum
MNPs are measured using pyrolysis GC-HRMS using a Frontier Multi-Shot Pyrolyzer with Auto-Shot Sampler interfaced to a Trace 1310 gas chromatography system and Thermo Scientific Q Exactive GC Orbitrap GC-MS/MS.
Infant weight
Time frame: 1 or 3 months +/- 2 weeks postpartum
Infant weight will be measured in duplicate on a digital scale accurate to the nearest 10 g
Infant length
Time frame: 1 or 3 months +/- 2 weeks postpartum
Infant length will be measured in duplicate to the nearest 0.1 cm using an Infantometer.
Infant skinfold thickness
Time frame: 1 or 3 months +/- 2 weeks postpartum
Infant skinfold thickness will be measured at four sites with Holtain skinfold callipers
1 secondary outcome
Maternal stool microbiome composition
Time frame: 1 or 3 months +/- 2 weeks postpartum
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jun 2026.
- Background: PubMed 28776036Geyer R, Jambeck JR, Law KL. Production, use, and fate of all plastics ever made. Sci Adv. 2017 Jul 19;3(7):e1700782. doi: 10.1126/sciadv.1700782. eCollection 2017 Jul.
- Background: PubMed 34749307Veidis EM, LaBeaud AD, Phillips AA, Barry M. Tackling the Ubiquity of Plastic Waste for Human and Planetary Health. Am J Trop Med Hyg. 2021 Nov 8;106(1):12-14. doi: 10.4269/ajtmh.21-0968. No abstract available.
- Background: PubMed 35682361Usman S, Abdull Razis AF, Shaari K, Azmai MNA, Saad MZ, Mat Isa N, Nazarudin MF. The Burden of Microplastics Pollution and Contending Policies and Regulations. Int J Environ Res Public Health. 2022 Jun 1;19(11):6773. doi: 10.3390/ijerph19116773.
- Background: PubMed 33127684Law KL, Starr N, Siegler TR, Jambeck JR, Mallos NJ, Leonard GH. The United States' contribution of plastic waste to land and ocean. Sci Adv. 2020 Oct 30;6(44):eabd0288. doi: 10.1126/sciadv.abd0288. Print 2020 Oct.
- Background: PubMed 34484127Kannan K, Vimalkumar K. A Review of Human Exposure to Microplastics and Insights Into Microplastics as Obesogens. Front Endocrinol (Lausanne). 2021 Aug 18;12:724989. doi: 10.3389/fendo.2021.724989. eCollection 2021.
- Background: PubMed 33388451Sendra M, Pereiro P, Figueras A, Novoa B. An integrative toxicogenomic analysis of plastic additives. J Hazard Mater. 2021 May 5;409:124975. doi: 10.1016/j.jhazmat.2020.124975. Epub 2020 Dec 26.
- Background: PubMed 22412286Rustagi N, Pradhan SK, Singh R. Public health impact of plastics: An overview. Indian J Occup Environ Med. 2011 Sep;15(3):100-3. doi: 10.4103/0019-5278.93198.
- Background: PubMed 34685192Yang H, He Y, Yan Y, Junaid M, Wang J. Characteristics, Toxic Effects, and Analytical Methods of Microplastics in the Atmosphere. Nanomaterials (Basel). 2021 Oct 17;11(10):2747. doi: 10.3390/nano11102747.
- Background: PubMed 32111046Yong CQY, Valiyaveettil S, Tang BL. Toxicity of Microplastics and Nanoplastics in Mammalian Systems. Int J Environ Res Public Health. 2020 Feb 26;17(5):1509. doi: 10.3390/ijerph17051509.
- Background: PubMed 35367073Leslie HA, van Velzen MJM, Brandsma SH, Vethaak AD, Garcia-Vallejo JJ, Lamoree MH. Discovery and quantification of plastic particle pollution in human blood. Environ Int. 2022 May;163:107199. doi: 10.1016/j.envint.2022.107199. Epub 2022 Mar 24.
- BackgroundLuqman A, Nugrahapraja H, Wahyuono RA, et al. Microplastic Contamination in Human Stools, Foods, and Drinking Water Associated with Indonesian Coastal Population. Environments. 2021;8(12):138. doi:10.3390/environments8120138
- Background: PubMed 33434834Zhang N, Li YB, He HR, Zhang JF, Ma GS. You are what you eat: Microplastics in the feces of young men living in Beijing. Sci Total Environ. 2021 May 1;767:144345. doi: 10.1016/j.scitotenv.2020.144345. Epub 2020 Dec 31.
Related trials for Infant Development
Not yet recruitingObservational study
Multimodal Mechanical, Tissue, Architectural, and Histological Evaluation of the Bone and Sutures of the Parietal Bone in an Infant With Craniosynostosis.
Craniostenosis
RecruitingObservational study
Natural History of Noncirrhotic Portal Hypertension
Cystic Fibrosis, Immunologic Deficiency Syndrome
Recruiting
Nutritional Maturity in Preterm Newborns (Premature Infant Oral Motor Intervention, PIOMI)
Preterm, Preterm Infant Development
Recruiting
Effect of Developmental Care on Very Low Birth Weight Infants
Intervention
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Tanya L Alderete, PhD principal investigator
Johns Hopkins Bloomberg School of Public Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Infant Development and Breast Feeding, run by Johns Hopkins Bloomberg School of Public Health at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tanya L Alderete, PhD (303-735-6249, tanya.alderete@colorado.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Microplastic composition in maternal breastmilk (time frame: 1 or 3 months +/- 2 weeks postpartum). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06107933, which also lists 106 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jun 2026.